Suppliers / Zhejiang Ruibang Laboratories

Zhejiang Ruibang Laboratories

China Updated 9 July 2026

Zhejiang Ruibang Laboratories is a contract manufacturer based in China. It holds 3 active US drug master files and 2 valid CEPs across a filed portfolio of 4 molecules. Its most recent recorded inspection, by US FDA, closed on 21 July 2016 as VAI.

3
active US DMFs
2
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 21 July 2016 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3001027745
Wenzhou, China Not on file

What they file, and where

Molecule Regulators Docs
Calcium SFDA (Saudi Arabia), US FDA 2
Cyclosporine EDQM, US FDA 2
Calcium Gluconate EDQM 1
Thiostrepton US FDA 1

Also appears on these molecule pages

Ciclosporin contract manufacturing Mupirocin contract manufacturing Simvastatin contract manufacturing

Comparing suppliers?

Choose your molecules and target markets. Zhejiang Ruibang Laboratories comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 21 July 2016.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability